IRIS
DEL PRINCIPE, MARIA ILARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 34.844
AS - Asia 5.908
EU - Europa 5.226
SA - Sud America 950
AF - Africa 93
OC - Oceania 31
Continente sconosciuto - Info sul continente non disponibili 13
Totale 47.065
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 34.634
SG - Singapore 2.728
IT - Italia 1.388
CN - Cina 1.137
DE - Germania 821
RU - Federazione Russa 774
BR - Brasile 770
HK - Hong Kong 664
VN - Vietnam 500
IE - Irlanda 490
UA - Ucraina 443
GB - Regno Unito 301
FR - Francia 270
JP - Giappone 199
KR - Corea 190
FI - Finlandia 187
NL - Olanda 137
CA - Canada 135
IN - India 114
SE - Svezia 113
PL - Polonia 78
AR - Argentina 60
AT - Austria 56
MX - Messico 51
ID - Indonesia 48
ES - Italia 45
BD - Bangladesh 39
TR - Turchia 35
CO - Colombia 31
IQ - Iraq 31
PH - Filippine 30
ZA - Sudafrica 30
BE - Belgio 29
AU - Australia 28
PK - Pakistan 24
IR - Iran 23
EC - Ecuador 20
VE - Venezuela 20
TH - Thailandia 19
UZ - Uzbekistan 19
SA - Arabia Saudita 17
CL - Cile 14
CZ - Repubblica Ceca 14
PY - Paraguay 13
EG - Egitto 12
IL - Israele 12
MA - Marocco 12
DZ - Algeria 11
LT - Lituania 11
MY - Malesia 11
NP - Nepal 11
PE - Perù 11
CH - Svizzera 10
LB - Libano 9
AE - Emirati Arabi Uniti 8
UY - Uruguay 8
DO - Repubblica Dominicana 7
EU - Europa 7
HR - Croazia 7
TN - Tunisia 7
TW - Taiwan 7
AL - Albania 6
GR - Grecia 6
KE - Kenya 6
RO - Romania 6
RS - Serbia 6
SN - Senegal 6
A2 - ???statistics.table.value.countryCode.A2??? 5
AZ - Azerbaigian 5
JM - Giamaica 4
JO - Giordania 4
LI - Liechtenstein 4
NO - Norvegia 4
PT - Portogallo 4
GT - Guatemala 3
HN - Honduras 3
KZ - Kazakistan 3
OM - Oman 3
SK - Slovacchia (Repubblica Slovacca) 3
BO - Bolivia 2
BY - Bielorussia 2
CR - Costa Rica 2
ET - Etiopia 2
GE - Georgia 2
HU - Ungheria 2
KG - Kirghizistan 2
KH - Cambogia 2
KW - Kuwait 2
MN - Mongolia 2
NG - Nigeria 2
NZ - Nuova Zelanda 2
PS - Palestinian Territory 2
QA - Qatar 2
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BH - Bahrain 1
BJ - Benin 1
BS - Bahamas 1
CM - Camerun 1
CY - Cipro 1
Totale 47.046
Salva come PNG Salva come JPEG
Città #
Woodbridge 9.113
Wilmington 8.874
Houston 5.162
Singapore 1.522
Fairfield 1.320
Ashburn 980
Chandler 975
San Jose 797
Ann Arbor 732
Hong Kong 644
Seattle 543
Beijing 483
Cambridge 464
Dublin 409
Rome 404
Jacksonville 354
New York 347
Dearborn 288
Medford 288
Santa Clara 274
The Dalles 220
Dallas 197
Los Angeles 190
Council Bluffs 185
Tokyo 180
Ho Chi Minh City 158
Lawrence 135
Moscow 117
Lauterbourg 108
Hanoi 105
Boardman 103
Buffalo 102
Milan 102
Zhengzhou 100
São Paulo 73
San Diego 72
Helsinki 57
Munich 56
Mülheim 52
Nuremberg 50
Warsaw 50
Chicago 47
Menlo Park 47
Montreal 46
Orem 44
Brooklyn 43
Creede 43
Frankfurt am Main 42
London 41
Bologna 40
North Bergen 39
Atlanta 35
Redondo Beach 35
Toronto 35
Engelhard 33
Jakarta 33
Lappeenranta 32
Seoul 32
Da Nang 30
Phoenix 29
Shanghai 29
Brussels 26
Redwood City 26
Chennai 25
Guangzhou 25
Columbus 22
Denver 22
Hefei 22
Stockholm 22
Vienna 22
Boston 21
Palo Alto 21
Rio de Janeiro 21
Amsterdam 20
Belo Horizonte 20
Norwalk 20
Haiphong 18
Johannesburg 18
Poplar 18
Turin 18
Mexico City 17
University Park 17
Center 16
San Francisco 16
Turku 16
Verona 16
Florence 15
Naples 15
Campinas 14
Nanjing 14
Shenzhen 14
Baghdad 13
Bari 13
Falls Church 13
Kraków 13
Kunming 13
Manchester 12
Mumbai 12
Quito 12
Bang Bai Mai 11
Totale 37.829
Salva come PNG Salva come JPEG
Nome #
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia 627
Femoral catheters: safety and efficacy in peripheral blood stem cell collection 540
AML-M0: A review of laboratory features and proposal of new diagnostic criteria 512
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments 487
Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML) 482
Clinical significance of CD38 expression in chronic lymphocytic leukemia 476
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. 470
Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. 469
Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia: Diagnostic Tools, Prophylaxis, and Therapy. 465
P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukaemia 448
Management of venous thromboembolism in patients with acute leukemia at high bleeding risk: a multi-center study 444
CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports. 442
Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patients 440
A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia 438
Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage 438
Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia 438
A case of oral mycosis fungoides successfully treated by combination of alemtuzumab and chemotherapy 436
NK Cell Inflammation in the Clinical Outcome of Colorectal Carcinoma 434
Multidimensional flow cytometry for detection of minimal residual disease in acute myeloid leukemia 432
Advances in the treatment of elderly and frail patients with acute myeloid leukemia 432
Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia 431
Lack of efficacy of imiquimod in patients with basal cell carcinoma previously treated with rituximab for B cell lymphoma: two case reports 430
Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia 428
ZAP-70 expression in B-cell chronic lymphocytic leukemia: evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgV(H) mutations 420
Cytogenetic and molecular diagnostic characterization combined to post-consolidation minimal residual disease assessment by flow-cytometry improves risk stratification in adult acute myeloid leukemia 419
A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia 419
Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. 418
Fluorescence in situ hybridization and conventional cytogenetics for the diagnosis of 11q23(+)/MLL+ translocation in leukaemia 418
Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation 416
Femoral catheters: safety and efficacy in peripheral blood stem cell collection 415
Thoracic cord compression caused by epidural extramedullary hematopoiesis during erythroid-stimulating agent therapy in two patients with myelodysplastic syndromes 413
Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. 412
Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells 409
Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey 408
Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia 404
Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study 401
Monitoring of minimal residual disease in acute myeloid leukemia 399
Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow 399
The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells 398
High sensitivity of flow cytometry improves detection of occult leptomeningeal disease in acute lymphoblastic leukemia and lymphoblastic lymphoma 397
Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications 396
A cluster of Geotrichum clavatum (Saprochaete clavata) infection in haematological patients: a first Italian report and review of literature 395
The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia 394
Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome 394
Circulating regulatory T cells in clinical monoclonal B-cell lymphocytosis. 393
Treatment of low-blast count AML using hypomethylating agents 390
Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy 388
Treatment of Acute Myeloid Leukemia with 20-30% Bone Marrow Blasts 388
Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients. 387
Combined analysis of bcl-2 and MDR1 proteins in 256 cases of acute myeloid leukemia 384
DIAGNOSTIC PERFORMANCE AND SAFETY OF BRONCHOALVEOLAR LAVAGE IN THROMBOCYTOPENIC HAEMATOLOGICAL PATIENTS FOR ASPERGILLOSIS DIAGNOSIS: A MONOCENTRIC, RETROSPECTIVE EXPERIENCE 383
Minimal Residual Disease as Biomarker for Optimal Biologic Dosing of ARA-C in Patients with Acute Myeloid Leukemia 378
Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations 376
Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features 373
Extensive toxic epidermal necrolysis following brentuximab vedotin administration 373
CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias 370
Rituximab single agent in age-related Epstein-Barr virus associated B cell disorder complicated by autoimmune anemia and pure red cell aplasia 369
Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia 368
NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. 365
Successful treatment of disseminated fusariosis with high dose liposomal amphotericin-B in a patient with acute lymphoblastic leukemia [4] 365
Epstein-Barr virus-positive lymphoma after alemtuzumab therapy for B-cell chronic lymphocytic leukemia 364
Apoptosis and immaturity in acute myeloid leukemia 361
Clinical significance of c.7544-7545 delCT NOTCH1 mutation in chronic lymphocytic leukaemia 361
Longitudinal detection of DNMT3AR882Htranscripts in patients with acute myeloid leukemia 361
Posaconazole oral suspension primary prophylaxis in acute leukemia and allogeneic stem cell transplant patients: can it be used without measurement of plasma concentration? 360
Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia 358
Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia 358
Thrombosis in adult patients with acute leukemia 357
CD69 is independently prognostic in chronic lymphocytic leukemia: acomprehensive clinical and biological profiling study 356
Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia. 352
Minimal residual disease as a biomarker for outcome prediction and therapy optimization in acute myeloid leukemia 351
Circulating regulatory T cells in "clinical" monoclonal B-cell lymphocytosis 348
CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia 347
Infections increase the risk of central venous catheter-related thrombosis in adult acute myeloid leukemia. 346
Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy 345
The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia 344
Risk allocation of adults patients with non-M3 acute myeloid leukemia 337
Minimal residual disease detection in pediatric acute myeloid leukemia: does flow cytometry score a point over molecular biology? 334
In vitro elimination of EGFR-overexpressing cancer cells by CD32A chimeric receptor T cells in combination with cetuximab or panitumumab 333
Hodgkin lymphoma in a mutated ZAP-70 negative B-cell Chronic Lymphocytic Leukemia patient 332
Evaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromes 332
Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. 330
Clinical significance of occult central nervous system disease in adult acute lymphoblastic leukemia. A multicenter report from the campus all network 320
Signature of B-CLL with different prognosis by Shrunken centroids of surface antigen expression profiling 315
FCγ chimeric receptor-engineered T cells: Methodology, advantages, limitations, and clinical relevance 312
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia 308
Fludarabine, Cytarabine and Gentuzumab Ozogamicin (FLA-GO) as Salvage Therapy and Bridge to Transplant in Adult Relapsed Acute Myeloid Leukemia (AML) Patients 303
The emerging role of measurable residual disease detection in AML in morphologic remission 302
Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study 295
Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse 294
Gemtuzumab ozogamicin in combination with intensive chemotherapy for relapsed/refractory acute myeloid leukemia 279
Real-life analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study 278
Case report: A Saprochaete clavata (Magnusiomyces clavatus) severe infection effectively treated with granulocyte transfusion in a young patient with myeloid sarcoma 252
An evaluation of enasidenib for the treatment of acute myeloid leukemia 243
Clinical relevance of an objective - limit of detection - limit of quantification - based flow cytometry approach for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial 225
Fungal infections of the central nervous system and paranasal sinuses in onco-haematologic patients. Epidemiological study reporting the diagnostic-therapeutic approach and outcome in 89 cases 221
Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness 219
Rhodotorula infection in haematological patient: Risk factors and outcome 217
Central nervous system fungal infections in allogeneic stem cell transplantation. Outcome of 24 recent cases and literature review 211
Characterization of FLT3-ITDmut acute myeloid leukemia: molecular profiling of leukemic precursor cells 208
Totale 37.702
Salva come PNG Salva come JPEG
Categoria #
all - tutte 129.989
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 129.989
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021309 0 0 0 0 0 0 0 0 0 0 233 76
2021/20221.672 62 172 46 48 33 171 100 113 139 165 92 531
2022/20232.609 286 230 230 261 157 472 288 163 285 46 134 57
2023/20241.219 104 52 135 35 99 331 57 83 43 31 35 214
2024/20254.639 181 890 531 245 85 285 403 208 485 473 391 462
2025/20268.075 860 419 990 689 858 335 1.017 1.068 1.025 731 83 0
Totale 47.905